Amy Saenger, PhD, DABCC

Associate Professor, Department of Laboratory Medicine and Pathology

Amy Saenger

Contact Info

saen0006@umn.edu

Office Phone 612-625-4702

Mailing Address:
Clinical Pathology/ARDL
MMC 609 Mayo
8609B (Campus Delivery Code)
420 Delaware St SE
Minneapolis, MN 55455

University of Washington (Clinical Chemistry), 2004-2006

PhD, University of Minnesota (Analytical and Biological Chemistry), 2004

BA, College of St. Catherine (Chemistry), 1999

Summary

Dr. Saenger is a clinical chemist whose research and publications focus on cardiac biomarkers such as troponin, natriuretic peptides and lipids/lipoproteins, as well as novel biomarkers for the detection of cardiovascular stress, damage, and heart failure. She is a faculty investigator and Scientific Director in the Advanced Research and Diagnostics Laboratory (ARDL). Her doctoral research for her degree in analytical chemistry from the University of Minnesota focused on mutations in acyl-CoA dehydrogenase enzymes. During her clinical chemistry fellowship training she expanded her research to include novel risk markers for oxidative stress and development of new tests using liquid chromatography / tandem mass spectrometry. She oversaw the development and implementation of numerous novel clinical and LC-MS/MS tests in her previous role as Medical Director of the Cardiovascular Laboratory and Central Clinical Laboratory at the Mayo Clinic.

Professional Associations

  • Fellow, National Academy of Clinical Biochemistry 2009
  • American Association for Clinical Chemistry 2004
  • Academy of Clinical Laboratory Physicians and Scientists 2006
  • American Chemical Society 2000
  • American Heart Association 2007
  • Iota Sigma Pi National Honor Society 1997

Research

Publications

See also PubMed

Gunsolus IL, Jaffe AS, Sexter A, Schulz K, Ler R, Lindgren B, Saenger AK, Love SA, Apple FS. Sex-specific 99th percentiles derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay: Comorbidities and statistical methods influence derivation of reference limits. Clin Biochem. 2017 Dec; 50(18):1073-1077. doi: 10.1016/j.clinbiochem.2017.09.009.

Whelton SP, Meeusen JW, Donato LJ, Jaffe AS, Saenger A, Sokoll LJ, Blumenthal RS, Jones SR, Martin SS. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. J Clin Lipidol. 2017 Jul - Aug;11(4):1065-1072. doi: 10.1016/j.jacl.2017.05.005. Epub 2017 Jun 1.

Amy K. Saenger, Olaia Rodriguez-Fraga, Ranka Ler, Jordi Ordonez-Llanos, Allan S. Jaffe, Jens Peter Goetze, Fred S. Apple. Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP PeptidesClinical Chemistry, vol. 63 no. 1 351-358. DOI: 10.1373/clinchem.2016.263749.

Fred S. Apple, Allan S. Jaffe, Scott Sharkey, Peter Kavsak, Michael C. Kontos, Amy K. Saenger, Stephen Smith. Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury. Clinical Chemistry, vol. 63 no. 1, 37-44 DOI: 10.1373/clinchem.2016.257428.

Karger AB, Saenger AK. A Setback to Universal Pediatric Lipid Screening and a Call for More Research. Clin Chem Feb 2017, 63 (2) 620-621; DOI: 10.1373/clinchem.2016.267989.

Moyer AM, Saenger AK, Willrich M, Donato LJ, Baumann NA, Block DR, Botz CM, Jaffe AS, Hanson CA, Karon BS. Implementation of a Clinical Decision Support Tool to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium and N-Terminal Pro-Brain Natriuretic Peptide in Intensive Care Unit Inpatients. Clinical Chemistry. 2016; 62(6): 824-30. doi: 10.1373/clinchem.2015.250514.

Leuke AJ, Meeusen JW, Donato LJ, Gray AV, Butterfield JH, Saenger AK. Analytical and Clinical Validation of an LC-MS/MS Method for Urine Leukotriene E4: A Marker of Systemic Mastocytosis. Clinical Biochemistry. 2016 Feb18. doi: 10.1016/j.clinbiochem.2016.02.007.

Donato LJ, Meeusen JW, Callanan H, Saenger AK, Jaffe AS. Advantages of the lipoprotein-associated phospholipase A2 activity assay. Clinical Biochemistry. 2016 Jan; 49(1-2): 172-5. doi: 10.1016/j.clinbiochem.2015.09.002.

Miller WL, Saenger AK, Grill DE, Slusser JP, Bayes-Genis A, Jaffe AS. Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. Journal of Cardiac Failure. 2015 Aug 14. doi: 10.1016/j.cardfail.2015.07.017.

Meeusen JW, Johnson JN, Gray A, Wendt P, Jefferies JL, Jaffe AS, Donato LJ, Saenger AK. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clinical Biochemistry. 2015 Dec;48(18):1337-40. doi: 10.1016/j.clinbiochem.2015.08.007.

Saenger AK and Haymond S. Utilization of Cardiac Troponin Assays in Adult and Pediatric Populations: Guideline Recommendations vs. Reality. Clinical Biochemistry. 2015 Dec;48(18):1213-8. doi: 10.1016/j.clinbiochem.2015.08.008.

Meeusen JW, Snozek CL, Baumann NA, Jaffe AS, Saenger AK. Reliability of Calculated Low-Density Lipoprotein Cholesterol. American Journal of Cardiology. 2015 May 21. doi: 10.1016/j.amjcard.2015.05.013. Epub ahead of print.

Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. American Journal of Hematology. 2015 Mar 8. doi: 10.1002/ajh.24001. Epub ahead of print.

Matyus SP, Braun PJ, Wolak-Dinsmore J, Saenger AK, Jeyarajah EJ, Shalaurova I, Warner SM, Fischer TJ, Connelly MA. HDL particle number measured on the Vantera®, the first clinical NMR analyzer. Clinical Biochemistry. 2015; 48(3):148-55. doi: 10.1016/j.clinbiochem.2014.11.017. Epub 2014 Nov 29.

Meeusen JW, Lueke AJ, Jaffe AS, Saenger AK. Validation of a proposed novel equation for estimating LDL cholesterol. Clinical Chemistry. 2014; 60(12):1519-23. doi: 10.1373/clinchem.2014.227710. Epub 2014 Oct 21.

Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle a noncardiac source of increased circulating concentrations of cardiac troponin T. Journal of the American College of Cardiology. 2011; 58(17): 1819-24. doi: 10.1016/j.jacc.2011.08.026. Epub 2011 Sep 29.

Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, Giannitsis E, Gustafson S, Handy B, Katus H, Melanson SE, Panteghini M, Venge P, Zorn M, Jarolim P, Bruton D, Jarausch J, Jaffe AS. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clinica Chimica Acta. 2011; 412(9-10):748-54. doi: 10.1016/j.cca.2010.12.034. Epub 2011 Jan 8.